Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Yuji Kitahata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9718-013X; OpenAlex author ID A5067731182. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 24

  1. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… First author DOI 10.1097/sla.0000000000006900↗
  2. Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes over 5-year follow-up. Co-author DOI 10.1016/j.suronc.2025.102248↗
  3. Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.1436↗
  4. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer. First author DOI 10.1007/s00432-023-05594-1↗
  5. Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy. Co-author DOI 10.1038/s41598-024-65093-2↗
  6. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  7. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  8. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2023.06.012↗
  9. Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Contro… Co-author DOI 10.1097/xcs.0000000000000408↗
  10. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by… Co-author DOI 10.1245/s10434-021-10985-0↗
  11. Advances in immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.944↗
  12. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreat… Co-author DOI 10.1016/j.ejso.2021.06.005↗
  13. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  14. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Co-author DOI 10.1007/s00423-020-01857-4↗
  15. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  16. Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Co-author DOI 10.1620/tjem.251.279↗
  17. Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14399↗
  18. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2018.12.015↗
  19. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12013↗
  20. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11389↗
  21. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  22. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Co-author DOI 10.1097/mpa.0000000000000634↗
  23. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.109↗
  24. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/j.1349-7006.2012.02214.x↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manabu Kawai · 20 shared papers, 2012–2025 · strength 2.30
  2. Hiroki Yamaue · 19 shared papers, 2012–2026 · strength 2.08
  3. Seiko Hirono · 19 shared papers, 2012–2026 · strength 2.06
  4. Motoki Miyazawa · 18 shared papers, 2012–2024 · strength 1.85
  5. Ken‐ichi Okada · 16 shared papers, 2012–2024 · strength 1.66
  6. Hideki Motobayashi · 7 shared papers, 2022–2026 · strength 1.36
  7. Atsushi Shimizu · 10 shared papers, 2012–2024 · strength 0.96
  8. Tomohiro Yoshimura · 4 shared papers, 2023–2025 · strength 0.78
  9. Atsushi Miyamoto · 4 shared papers, 2022–2025 · strength 0.72
  10. Ken‐ichi Okada · 3 shared papers, 2014–2024 · strength 0.40
  11. Keiko Kamei · 2 shared papers, 2024–2026 · strength 0.38
  12. Masayuki Sho · 2 shared papers, 2023–2026 · strength 0.38
  13. Takashi Tamura · 3 shared papers, 2020–2023 · strength 0.36
  14. Masayuki Kitano · 3 shared papers, 2020–2023 · strength 0.36
  15. Kohei Nakata · 2 shared papers, 2024 · strength 0.35
  16. Masafumi Nakamura · 2 shared papers, 2024 · strength 0.35
  17. Akimasa Nakao · 2 shared papers, 2017–2026 · strength 0.29
  18. Sohei Satoi · 2 shared papers, 2016–2026 · strength 0.28
  19. Ken Kouda · 2 shared papers, 2020–2022 · strength 0.26
  20. Michiaki Unno · 2 shared papers, 2020–2024 · strength 0.26
  21. Masaaki Hidaka · 1 shared paper, 2026 · strength 0.23
  22. Kenjiro Kimura · 1 shared paper, 2026 · strength 0.23
  23. Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
  24. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.23
  25. Ryo Morimura · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.